Equities

XRF Scientific Ltd

XRF Scientific Ltd

Actions
Health CareMedical Equipment and Services
  • Price (USD)0.00
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Dec 30 1899.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

XRF Scientific Limited is an Australia-based company, which manufactures and sells chemicals, equipment and accessories to production mines, construction material companies and commercial analytical laboratories, in Australia and overseas. These finished goods are primarily used in the preparation of samples for analysis. The Company's segments include Capital Equipment, Precious Metals and Consumables. The Capital Equipment segment manufactures automated fusion equipment, high temperature test and production furnaces, laboratory jaw crushers and general laboratory equipment. The Precious Metals segment manufactures products for the laboratory and industrial platinum alloy markets. The Consumables segment manufactures chemicals and other supplies for analytical laboratories. Its products and services include Fusion Equipment, Flux & Chemicals, Platinum Labware, Precision Platinum and Lab Equipment. Its subsidiaries include XRF Chemicals Pty Ltd, XRF Labware Pty Ltd and others.

  • Revenue in AUD (TTM)56.79m
  • Net income in AUD8.43m
  • Incorporated2004
  • Employees--
  • Location
    XRF Scientific Ltd86 Guthrie Street, Osborne ParkPERTH 6017AustraliaAUS
  • Phone+61 89244-0600
  • Fax+61 89244-9611
  • Websitehttps://www.xrfscientific.com
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.